Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Analyst Downgrades, and What Investors Watch Next (Dec. 22, 2025)
BioMarin agreed to acquire Amicus Therapeutics for $14.50 per share in cash, valuing Amicus at $4.8 billion. FOLD traded near $14.22 on December 22, reflecting market expectations for deal completion and timing. The transaction is expected to close in Q2 2026, pending regulatory and shareholder approvals. Either party may terminate if not closed by June 19, 2026, with a $175 million breakup fee.